Vyjuvek: a gene-therapy gel heals wounds in "butterfly" children
Published · Researched 2026-09-22
What happened (dated facts)
In May 2023, the U.S. FDA approved Vyjuvek (beremagene geperpavec), the first redosable gene therapy — a topical gel for dystrophic epidermolysis bullosa (DEB), the "butterfly skin" disease in which the slightest friction tears the skin into chronic, painful wounds. In the Phase 3 GEM-3 trial, 65% of treated wounds were completely closed at six months versus 26% with placebo, and 68% versus 23% at three months — with no treatment-related serious adverse events reported in the extension coverage. The gel delivers a working copy of the COL7A1 gene directly to wounds during routine dressing changes, and it can be reapplied because it does not trigger the immunity that blocks redosing of systemic gene therapies.
Why it is genuinely positive
Children with DEB live bandaged like burn victims, with wounds that never heal. A gel applied at home during dressing changes that closes two-thirds of wounds — safely and repeatedly — turns an untreatable genetic disease into something families can actively heal.
Social pulse
Strong dermatology-press circulation around the May 2023 approval and GEM-3 results. Targeted Threads searches did not return direct posts about Vyjuvek in this session. The social layer here is health media rather than viral patient posts.
Verified quotes
None captured.
Verification
- Tier: 2
- Primary source: Dermatology Advisor coverage of the Phase 3 results and approval (https://www.dermatologyadvisor.com/news/vyjuvek-approval-phase-3-gem-3-trial/). Proves: May 2023 approval; 65% vs 26% complete closure at 6 months; 68% vs 23% at 3 months; no treatment-related SAEs.
- Social sources: health-press layer + targeted Threads searches (direct story posts not captured — noted honestly). Proves: sustained coverage and community relevance via health media.
- Positivity check: approved, redosable gene therapy with large measured wound-closure benefit and clean safety — genuine.
Key facts
| Fact | Value | Source | Date |
|---|---|---|---|
| FDA approval | May 2023 (Vyjuvek, beremagene geperpavec) | Dermatology Advisor | 2023-05 |
| Status | First redosable gene therapy; topical gel for DEB | Dermatology Advisor | 2023-05 |
| GEM-3, 6 months | 65% complete wound closure vs 26% placebo | Dermatology Advisor | 2023 |
| GEM-3, 3 months | 68% vs 23% | Dermatology Advisor | 2023 |
| Safety | No treatment-related serious adverse events reported | Dermatology Advisor | 2023 |
UNVERIFIED points
- Social-layer posts about Vyjuvek were not yet observed; tier cannot be finalized until they are.
Sources
- Primary source: Dermatology Advisor coverage of the Phase 3 results and approval ( — retrieval date not recorded